A
Altor BioScience
Researches and develops immunotherapeutic agents for the treatment of cancer, viral infections and autoimmune diseases
About Altor BioScience
ImmunityBio, Inc. is a privately held immunotherapy company specializing in the development of advanced biological molecules to treat cancer and infectious diseases. The company operates in the biotechnology sector, focusing on creating therapies that harness the body's immune system to fight diseases. ImmunityBio serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. The company’s business model revolves around research and development, clinical trials, and partnerships with other biotech firms to bring innovative treatments to market. Revenue is generated through licensing agreements, product sales, and collaborative research funding. ImmunityBio's portfolio includes albumin-linked chemotherapeutics, peptides, fusion proteins, cytokines, monoclonal antibodies, and both adenovirus and yeast vaccine therapies. The company is also actively involved in the development of a novel adenovirus COVID-19 vaccine, showcasing its commitment to addressing urgent global health challenges.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2002
- Headquarters
- Miramar, United States
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 83.6/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Drug Development, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Jun 2017 | $290M | — | NantCell | Nantworks | — |
| GROWTH EQUITY VCOther financing | Mar 2017 | $30M | — | Undisclosed | — |
Growth signals
Latest recorded traffic for Altor BioScience is 0 monthly website visits. Altor BioScience's team grew 350% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
National Institute of Neurological Disorders and Stroke
Bill & Melinda Gates Foundation
National Cancer Institute (NCI)
Series A2 investors entered at this stage
Sanderling Ventures
Radius Ventures
Other known investors2 additional known investors
NantCell | Nantworks
Techno Venture Management
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Altor BioScience on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Altor BioScience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.